Additional Advances in Hemophilia Research and Clinical Trials With Robert F. Sidonio, Jr., MD, MSc

View the full article on Oncology Data Advisor: https://bit.ly/48b8AVo Start the full CME activity here: https://www.youtube.com/watch?v=cJ0klW_mNzI&feature=youtu.be View and download the slide deck here: https://www.slideshare.net/slideshow/raising-the-bar-for-hemophilia-management-47c1/282931071 In this edition of Additional Advances, Robert F. Sidonio, Jr., MD, MSc, Professor of Pediatrics and Medical Director of Hemophilia at the Georgia Center for Bleeding and Clotting Disorders, Children’s Healthcare of Atlanta, shares the latest clinical trial and real-world insights shaping hemophilia care. As co-chair of i3 Health’s symposium and online activity, Raising the Bar for Hemophilia Management, Dr. Sidonio discusses how ongoing experience with newer therapies continues to refine patient selection, dosing, and day-to-day implementation. He reviews key considerations for rebalancing agents and the importance of guardrails in dosing and monitoring, along with emerging data related to inhibitor risk mitigation, including findings from a study of rurioctocog alfa. Dr. Sidonio also discusses the Atlanta Protocol, an institutional approach that combines emicizumab with factor VIII to support immune tolerance, and why higher factor VIII dosing may be more effective than lower doses for inducing tolerance. The conversation highlights the expanding hemophilia treatment toolkit, including bispecific antibodies, extended half-life factors, anti TFPI agents, and siRNA therapies, as well as the evolving role of gene therapy. In recognition of Bleeding Disorders Awareness Month, Dr. Sidonio also emphasizes the need to broaden awareness beyond the most severe phenotypes and to include women and girls with hemophilia.